Jasvinder A Singh1, David G Lewallen. 1. Medicine Service and Center for Surgical Medical Acute Care Research and Transitions (C-SMART), Birmingham VA Medical Center, Birmingham, Alabama, USA. jasvinder.md@gmail.com
Abstract
OBJECTIVE: To characterize whether medical comorbidity predicts persistent moderate-severe pain after total hip arthroplasty (THA). METHODS: We analyzed the prospectively collected data from the Mayo Clinic Total Joint Registry for patients who underwent primary or revision THA between 1993 and 2005. Using multivariable-adjusted logistic regression analyses, we examined whether certain medical comorbidities were associated with persistent moderate-severe hip pain 2 or 5 years after primary or revision THA. Odds ratios (ORs), along with 95% confidence intervals (CIs) and P value, are presented. RESULTS: The primary THA cohort consisted of 5,707 THAs and 3,289 THAs at 2 and 5 years, and revision THA, 2,687 and 1,627 THAs, respectively. In multivariable-adjusted logistic regression models, in the primary THA cohort, renal disease was associated with lower odds of moderate-severe hip pain (OR 0.6; 95% CI 0.3, 1.0) at 2 years. None of the comorbidities were significantly associated at 5 years. In the revision THA cohort, heart disease was significantly associated with higher risk (OR 1.7; 95% CI 1.1, 2.6) at 2 years and connective tissue disease with lower risk (OR 0.5; 95% CI 0.3, 0.9) of moderate-severe hip pain at 5-year follow-up. CONCLUSION: This study identified new correlates of moderate-severe hip pain after primary or revision THA, a much-feared outcome of hip arthroplasty. Patients with these comorbidities should be informed regarding the risk of moderate-severe index hip pain, so that they can have a fully informed consent and realistic expectations. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
OBJECTIVE: To characterize whether medical comorbidity predicts persistent moderate-severe pain after total hip arthroplasty (THA). METHODS: We analyzed the prospectively collected data from the Mayo Clinic Total Joint Registry for patients who underwent primary or revision THA between 1993 and 2005. Using multivariable-adjusted logistic regression analyses, we examined whether certain medical comorbidities were associated with persistent moderate-severe hip pain 2 or 5 years after primary or revision THA. Odds ratios (ORs), along with 95% confidence intervals (CIs) and P value, are presented. RESULTS: The primary THA cohort consisted of 5,707 THAs and 3,289 THAs at 2 and 5 years, and revision THA, 2,687 and 1,627 THAs, respectively. In multivariable-adjusted logistic regression models, in the primary THA cohort, renal disease was associated with lower odds of moderate-severe hip pain (OR 0.6; 95% CI 0.3, 1.0) at 2 years. None of the comorbidities were significantly associated at 5 years. In the revision THA cohort, heart disease was significantly associated with higher risk (OR 1.7; 95% CI 1.1, 2.6) at 2 years and connective tissue disease with lower risk (OR 0.5; 95% CI 0.3, 0.9) of moderate-severe hip pain at 5-year follow-up. CONCLUSION: This study identified new correlates of moderate-severe hip pain after primary or revision THA, a much-feared outcome of hip arthroplasty. Patients with these comorbidities should be informed regarding the risk of moderate-severe index hip pain, so that they can have a fully informed consent and realistic expectations. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
Entities:
Keywords:
Arthroplasty; Function; Functional Limitation; Joint Replacement; Outcomes; Pain; Patient-Reported Outcomes; Primary; Total Hip Replacement
Authors: H A Bischoff-Ferrari; E A Lingard; E Losina; J A Baron; E M Roos; C B Phillips; N N Mahomed; J Barrett; J N Katz Journal: Arthritis Rheum Date: 2004-10-15
Authors: W F Peter; J Dekker; C Tilbury; R L Tordoir; S H M Verdegaal; R Onstenk; M R Bénard; S B Vehmeijer; M Fiocco; H M Vermeulen; H M J van der Linden-van der Zwaag; R G H H Nelissen; T P M Vliet Vlieland Journal: Rheumatol Int Date: 2015-01-14 Impact factor: 2.631
Authors: Eva N Glassou; Alma B Pedersen; Peter K Aalund; Sebastian B Mosegaard; Torben B Hansen Journal: Acta Orthop Date: 2018-04-06 Impact factor: 3.717